Cyllene Therapeutics
PrivateLast Round
Series C
Jul 7, 2026
Total Funding Raised
$93.95M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Cyllene Therapeutics is a biotechnology company that develops pinpoint DNA medicine solutions using a non-replicative Herpes Simplex Virus type 1 (nrHSV-1) vector platform to treat chronic neurological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cyllene Therapeutics Comparables
Compare Cyllene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Replay | 76% | |
| Sumitomo Pharma Co., Ltd. | 74% | |
| Guangzhou Yinming Biomedical Technology | 64% | |
Cyllene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 7, 2026 | ||||
| Series B | Feb 20, 2025 | ||||
| Series A Extension | Jul 13, 2023 | ||||
| Series A | Mar 1, 2021 | ||||
| Seed | May 1, 2019 |
Key People
Founding team and executive leadership
Cyllene Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SCI Ventures | Series B |
| GordonMD Global Investments | Series C |
| Andera Partners | Series C, Series B |
| M Ventures | Series C |
| Bpifrance | Series B, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 7, 2026
$38M round led by GordonMD Global Investments and M Ventures.
- Jun 19, 2026
Monthly visitors increased 39% MoM.
Cyllene Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Cyllene Therapeutics's valuation, stock price, and market status.